Development of a biosensor for phosphorylated Tau 181 protein detection in Early-Stage Alzheimer’s disease

Schneider, Maria Eduarda; Guillade, Lucía; Correa‐Duarte, Miguel A.; Moreira, Felismina T.C.

doi:10.1016/j.bioelechem.2022.108057

Cited by 16 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Technique Sensing platform Sample Linear range LOD Refs. EIS Ab/Protein G/3,3'-dithiobis(sulfosuccinimidyl propionate) (DTSSP)/Gold Electrode BSA & Human serum 0.01 pM to 10 nM 0.03 pM 63 DPV Aptamer-Au-CS bioconjugate /BSA/Ab/MPA/Gold Electrode Human serum 0.5 pM to 100 pM 0.42 pM 64 EIS 3-aminophenol MIP/C-SPE PBS 2.18 pM to 2.18 nM 0.024 pM 65 EIS n-butylamine/Ab/lipoic acid/Au Electrode PBS – 100 μg/mL 66 DPV carbon nanocomposite film composed of MWCNTs, rGO, and CS/Gold Electrode Human serum 0.5–80 fM 0.46 fM 67 DPV Apt/AuNPs/Paper-based vertical graphene electrode (VGE) Blood 0.1 pg/mL to 1 ng/mL 0.034 pg/mL 68 SWV, CV Ab/MWCNTs-PAH/Pt/C-SPE Serum 8.6–1100 pg/mL 0.24 pg/mL 69 Amperometric HRP-DAb/tau/capture antibody/AuNPs-PAMAM/C-SPE Undiluted human plasma and brain tissue extracts 11–800 pg mL …”

Section: Resultsmentioning

confidence: 99%

Application of Pt@ZIF-8 nanocomposite-based electrochemical biosensor for sensitive diagnosis of tau protein in Alzheimer’s disease patients

Chakari-Khiavi,

Mirzaie,

Khalilzadeh

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a progressive brain disorder characterized by the ongoing decline of brain functions. Studies have revealed the detrimental effects of hyperphosphorylated tau (p-tau) protein fibrils in AD pathogenesis, highlighting the importance of this factor in the early-stage detection of AD conditions. We designed an electrochemical immunosensor for quantitative detection of the cis conformation of the p-tau protein (cis-p-tau) employing platinum nanoparticles (Pt NPs) supported on zeolitic imidazolate frameworks (ZIF) for modifying the glassy carbon electrode (GCE) surface. Under optimum conditions, the immunosensor selectively and sensitively detected cis-p-tau within the broad linear range of 1 fg mL−1 to 10 ng mL−1 and the low limit of detection (LOD) of 1 fg mL−1 with desired reproducibility and stability. Furthermore, the fabricated immunosensor's performance was examined for the cis-p-tau analysis in the serum of AD patients, indicating its accuracy and feasibility for real-sample analysis. Notably, this is the first application of Pt@ZIF-8 nanocomposite in fabricating a valid immunosensor for selective cis-p-tau detection, even in the presence of trans-p-tau. It is worth mentioning that the enzyme-linked immunosorbent assay (ELISA) reference technique is not able to evaluate pico- or femtomolar concentrations of cis-p-tau, making the fabricated immunosensor superior for early-stage measurement and screening of AD.

show abstract

Section: Resultsmentioning

confidence: 99%

Application of Pt@ZIF-8 nanocomposite-based electrochemical biosensor for sensitive diagnosis of tau protein in Alzheimer’s disease patients

Chakari-Khiavi,

Mirzaie,

Khalilzadeh

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In cases where the capacitive behavior is not ideal, it is represented by a frequencydependent element called a constant phase element (CPE), instead of C dl for the double layer, which is defined by a value and the coefficient of CPE. The impedance CPE is defined as in (2).…”

Section: Resultsmentioning

confidence: 99%

“…Point-of-care biosensors present a promising solution for the regular monitoring of biomarkers for the early diagnosis of diseases like cancer [ 1 ], Alzheimer’s disease [ 2 ] and metabolic disorders [ 3 ]. Biosensors employ either a labeled approach or a label-free approach as the underlying principle.…”

Section: Introductionmentioning

confidence: 99%

Label-Free, Impedance-Based Biosensor for Kidney Disease Biomarker Uromodulin

Vora,

Kordas,

Seidl

2023

Sensors

View full text Add to dashboard Cite

We demonstrate the development of a label-free, impedance-based biosensor by using a passivation layer of 50-nm tantalum pentoxide (Ta2O5) on interdigitated electrodes (IDE). This layer was fabricated by atomic layer deposition (ALD) and has a high dielectric constant (high-κ), which improves the capacitive property of the IDE. We validate the biosensor’s performance by measuring uromodulin, a urine biomarker for kidney tubular damage, from artificial urine samples. The passivation layer is functionalized with uromodulin antibodies for selective binding. The passivated IDE enables the non-faradaic impedance measurement of uromodulin concentrations with a measurement range from 0.5 ng/mL to 8 ng/mL and with a relative change in impedance of 15 % per ng/mL at a frequency of 150 Hz (log scale). This work presents a concept for point-of-care biosensing applications for disease biomarkers.

show abstract

“…There are several potential POC devices reporting the analysis of inflammation biomarkers, such as cortisol [ 157 – 159 ], C-reactive protein [ 160 – 162 ], Tau protein [ 163 – 166 ], or S-100B [ 167 ]. For example, cortisol was analyzed using an impedimetric SPCE-modified electrochemical cell [ 157 ] and a voltammetric Au-interdigitated modified microelectrode [ 158 ] from saliva and plasma, respectively.…”

Section: Biomarkers Involved In Inflammatory Diseasesmentioning

confidence: 99%

Point-of-care electrochemical testing of biomarkers involved in inflammatory and inflammatory-associated medical conditions

et al. 2022

View full text Add to dashboard Cite

Recent years have shown that the diagnosis and monitoring of biomarkers involved in inflammatory-associated medical conditions such as cancer, neurological disorders, viral infections, or daily physical activities offer real benefits in increasing the quality of medical care and patient life quality. In this context, the use of integrated and portable platforms as point-of-care testing devices for biomedical analysis to enable early disease diagnosis and monitoring, which can be successfully used even at the patient’s bed, is an emergency nowadays. The development of low-cost, miniaturized, and portable, user-friendly devices that provide an answer in a timely manner, such as electrochemical sensors, is relevant for the elaboration of point-of-care testing devices. This review focuses on the recent progress in bioanalysis of both specific biomarkers and inflammatory-associated biomarkers present in several diseases like neoplasia, severe neurological disorders, viral infections, and usual physical activity and provides an overview of the state of the art over the most recent electrochemical (bio)sensors for the detection of inflammation-related biomarkers. Future perspectives of point-of-care testing to improve healthcare management are also discussed. Graphical abstract

show abstract

Development of a biosensor for phosphorylated Tau 181 protein detection in Early-Stage Alzheimer’s disease

Cited by 16 publications

References 26 publications

Application of Pt@ZIF-8 nanocomposite-based electrochemical biosensor for sensitive diagnosis of tau protein in Alzheimer’s disease patients

Application of Pt@ZIF-8 nanocomposite-based electrochemical biosensor for sensitive diagnosis of tau protein in Alzheimer’s disease patients

Label-Free, Impedance-Based Biosensor for Kidney Disease Biomarker Uromodulin

Point-of-care electrochemical testing of biomarkers involved in inflammatory and inflammatory-associated medical conditions

Contact Info

Product

Resources

About